1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Indonesia Pharmaceuticals and Healthcare Report Q1 2017

Indonesia Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 125 pages

Includes 3 FREE quarterly updates


>BMI View:
Multinational pharmaceutical firms operating in Indonesia will continue to face a significant competitive threat from domestic companies. These firms are well established, with a presence across numerous sub-sectors including logistics, consumer healthcare and prescription drugs. Other firms, including government-owned Kimia Farma, have expanded into the provision of medical services, which will give them a distinct advantage in marketing its products. Moreover, generic drugs will remain the mainstay of the Indonesian medicine market. Indonesia's health insurance scheme will maintain this dominance through its mandate that patients be prescribed generic substitutes when possible.

Headline Expenditure Projections

- Pharmaceuticals: IDR77.6trn (USD5.8bn) in 2015 to IDR85.6trn (USD6.4bn) in 2016; +10.2% growth in local currency terms and +10.9% in US dollar terms. Forecast held steady from previous quarter.

- Healthcare: IDR330trn (USD24.7bn) in 2015 to IDR367trn (USD27.6bn) in 2016; +11.2% growth in local currency terms and +11.9% in US dollar terms. Forecast held steady from previous quarter.

Table Of Contents

Indonesia Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Indonesia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Indonesia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Indonesia 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Indonesia 2014-2020) 31
Industry Risk/Reward Index 32
Asia Pacific Risk/Reward Index - Q1 2017 32
Indonesia Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Intellectual Property Issues 44
Pricing Regime 48
Reimbursement Regime 49
Industry Trends And Developments 50
Market Overview 50
Table: UN Millennium Development Goals For Indonesia 51
Healthcare Sector 52
Table: Examples Of JKN Benefits 53
Table: Healthcare Resources (Indonesia 2010-2015) 54
Table: Healthcare Personnel (Indonesia 2010-2015) 54
Table: Healthcare Activity (Indonesia 2010-2015) 55
Research and Development 55
Clinical Trials 56
Epidemiology 58
Table: Estimated Number Of New Cases Of Cancer In Indonesia 60
Competitive Landscape 63
Research-Based Industry 63
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions 64
Table: Multinational Market Activity 65
Generic Drugmakers 66
Pharmaceutical Distribution 67
Pharmaceutical Retail Sector 68
Company Profile 71
Bayer 71
Darya-Varia Group 74
GlaxoSmithKline 77
Indopharma 80
Kimia Farma 83
Merck and Co 88
Merck Group 91
Novartis 94
Pfizer 97
PT Biofarma 100
PT Kalbe Farma 103
Sanofi 108
Soho Group 111
Demographic Forecast 114
Demographic Outlook 114
Table: Population Headline Indicators (Indonesia 1990-2025) 115
Table: Key Population Ratios (Indonesia 1990-2025) 115
Table: Urban/Rural Population and Life Expectancy (Indonesia 1990-2025) 116
Table: Population By Age Group (Indonesia 1990-2025) 116
Table: Population By Age Group % (Indonesia 1990-2025) 117
Glossary 119
Methodology 121
Pharmaceutical Expenditure Forecast Model 121
Healthcare Expenditure Forecast Model 121
Notes On Methodology 122
Risk/Reward Index Methodology 123
Index Overview 124
Table: Pharmaceutical Risk/Reward Index Indicators 124
Indicator Weightings 125

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.